Evidence map›Paper›PMID 41699671›Full record

ArticleRespiratory research2026

Prevalence and clinical outcomes of fibrotic interstitial lung disease in ANCA associated vasculitis: a single-centre, retrospective, cohort study.

Claudio Tirelli, Sabrina Mira, Tommaso Schioppo, Sara Mirijaj, Marta Italia, Francesca Pescol, Simone Frizzarin, Cristina Albrici, Fausta Alfano, Lucia Sacchi and 3 more

Abstract read
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Claudio Tirelli *Department of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Sabrina Mira *Department of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Tommaso SchioppoDepartment of Health Sciences, Internal Medicine Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Sara MirijajDepartment of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Marta ItaliaDepartment of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Francesca PescolDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100, Pavia, Italy.
Simone FrizzarinDepartment of Health Sciences, Renal Division, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Cristina AlbriciDepartment of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Fausta AlfanoDepartment of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Lucia SacchiDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100, Pavia, Italy.
Gian Marco PoddaDepartment of Health Sciences, Internal Medicine Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Mario Gennaro CozzolinoDepartment of Health Sciences, Renal Division, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy.
Michele MondoniDepartment of Health Sciences, Respiratory Unit, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, 20142, Milan, Italy. michele.mondoni@unimi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may affect multiple organs and interstitial lung disease (ILD) might be the first manifestation. Limited and discordant data are available on the prevalence of ILD in patients with AAV. Little is known about prognostic outcomes of these patients. The primary aim of the study was to determine the prevalence of fibrotic ILD in a cohort of AAV patients followed-up in a University Hospital in Italy. Clinical and prognostic outcomes of AAV-ILD were also assessed.

methodsData from 71 AAV patients (mean age 60.3 ± 16 years; female 58.9%) were retrospectively collected and analyzed.

resultsOverall ILD prevalence was 50.7%. Fibrotic ILDs represented 32.4% with a variable distribution according to AAV diagnosis: microscopic polyangiitis (MPA) 66.7%, eosinophilic granulomatosis with polyangiitis (EGPA) 41.1%, granulomatosis with polyangiitis (GPA) 31.8%. The presence of ILD was significantly different across AAV subgroups. Fibrotic ILD was more prevalent in MPA (60%) than EGPA (11.8%) and GPA (9.1%) and most frequently associated with usual interstitial pneumonia (UIP) radiologic pattern. The presence of ANCA was significantly associated with fibrotic ILDs (p = 0.01). In univariate analysis, only MPA increased the risk of having ILD (OR 2 (CI 95%: 0.96–4.67). Mortality was significantly higher in patients with ILD (p = 0.01), with fibrotic forms influencing this finding and MPA showing the highest mortality.

conclusionsFibrotic ILDs are common in patients with AAV and influence clinical and prognostic outcomes. MPA is the most frequent AAV associated to fibrotic ILD. ILD should be investigated at diagnosis in all patients with AAV, since early detection might impact the prognosis of these patients.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLung Diseases, InterstitialPulmonary FibrosisAdultAgedCohort StudiesFemaleHumansItalyMaleMiddle AgedPrevalencePrognosisRetrospective StudiesANCAEGPAFibrosisGPAHRCTILDMortalityMPAUIPVasculitis

Identifiers

PMID41699671
PMCPMC13014989

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.